文献速递临床试验与 GCP流行病学与生物统计

贝叶斯增强两阶段设计在二期临床试验中的误差控制方法

Bayesian enhancement two-stage design with error control for phase II clinical trials.
PubMed 文献 · Stat Med · 2020-08-27

针对Simon两阶段设计接受药物时H1后验概率低的问题,提出贝叶斯增强两阶段(BET)设计,但最高后验密度(HPD)区间长度缺乏透明性。为此提出以后验错误率替代HPD区间长度的BETEC设计,通过模拟和两个近期临床试验验证,表明BETEC能平衡后验假阳性率与假阴性率且解释直观。

要点

  • BETEC设计用后验错误率替代HPD区间长度校准参数,解释更直观。
  • BETEC可平衡后验假阳性率与假阴性率,提升试验特征稳定性。
  • BETEC可作为二期单臂试验的替代设计工具。

核心结论

  • BETEC设计高效且直观,可作为二期单臂试验的替代工具箱。

研究设计与样本

  • 方法学研究,提出BETEC设计并通过广泛模拟研究比较BET与Simon设计。
  • 进一步将BETEC应用于两项近期临床试验并与其他竞争设计比较性能。

主要发现

  • BET设计接受药物时H1后验概率低,BET通过HPD区间长度等校准参数。
  • BETEC用后验错误率替代HPD区间长度,能平衡后验假阳性率与假阴性率。

关键数值与推荐

  • BET设计基于HPD区间长度、H0和H1的后验概率校准设计参数。
  • BETEC设计以后验错误率替代HPD区间长度进行校准。

临床怎么用

  • BETEC可用于二期单臂临床试验的设计与实施。

局限性

  • 原文未明确报告BETEC的具体局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Phase II clinical trials make a critical decision of go or no-go to a subsequent phase III studies. A considerable proportion of promising drugs identified in phase II trials fail the confirmative efficacy test in phase III. Recognizing the low posterior probabilities of H1 when accepting the drug under Simon's two-stage design, the Bayesian enhancement two-stage (BET) design is proposed to strengthen the passing criterion. Under the BET design, the lengths of highest posterior density (HPD) intervals, posterior probabilities of H0 and H1 are computed to calibrate the design parameters, aiming to improve the stability of the trial characteristics and strengthen the evidence for proceeding the drug development forward. However, from a practical perspective, the HPD interval length lacks transparency and interpretability. To circumvent this problem, we propose the BET design with error control (BETEC) by replacing the HPD interval length with the posterior error rate. The BETEC design can achieve a balance between the posterior false positive rate and false negative rate and, more importantly, it has an intuitive and clear interpretation. We compare our method with the BET design and Simon's design through extensive simulation studies. As an illustration, we further apply BETEC to two recent clinical trials, and investigate its performance in comparison with other competitive designs. Being both efficient and intuitive, the BETEC design can serve as an alternative toolbox for implementing phase II single-arm trials.

来源:Stat Med,查看原文。版权归原作者所有。

引用

  1. Jin H, Yin G. Bayesian enhancement two-stage design with error control for phase II clinical trials. Stat Med. 2020. PMID: 32854163. doi:10.1002/sim.8734

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。